Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Switching from daily somatropin to once-weekly somapacitan in adults with growth hormone deficiency maintains lean mass, improves functional outcomes, but may increase adiposity indices, highlighting a trade-off in metabolic effects during
In 180 adolescents and young adults with childhood-onset GH deficiency, glucagon-stimulated GH secretion was driven mainly by hypothalamic-pituitary disease severity, while BMI had little independent effect after accounting for etiology.
Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.
Once-weekly lonapegsomatropin (Skytrofa) is now FDA-approved for adult growth hormone deficiency, offering a more convenient alternative to daily injections with demonstrated efficacy and safety.